Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

    Arpita Dutt headshot

    Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug

    Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.

      Mark Vickery headshot

      Top Research Reports for UnitedHealth Group, Union Pacific & Biogen

      Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (UNH), Union Pacific Corporation (UNP) and Biogen Inc (BIIB).

        Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer

        Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.

          Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?

          BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Biogen's Fampyra Conditional Approval Converted to Standard

            Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

              Arpita Dutt headshot

              Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

              Quite a few deals were announced this week including by companies like Biogen (BIIB).

                Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

                  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson

                    What's in the Cards for Ionis (IONS) this Earnings Season?

                    Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.

                      Mark Vickery headshot

                      Top Research Reports for May 4, 2017

                      Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).

                        Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss

                        Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.

                          Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

                          Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

                            Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong

                            Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.

                              Biogen (BIIB) Beats on Q1 Earnings and Revenue

                              BIIB???s first quarter 2017 earnings were better-than expected. The company posted earnings of $5.20 per share while our consensus called for EPS of $4.97.

                                Arpita Dutt headshot

                                3 Key Factors to Look Out for in Biogen's Q1 Results

                                With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

                                  Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

                                  As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.

                                    What's in Store for Biogen (BIIB) this Earnings Season?

                                    Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.

                                      Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

                                      Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

                                        Biogen to License Alzheimer Candidate from Bristol-Myers

                                        Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

                                          AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

                                          AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

                                            Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline

                                            Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.

                                              Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge

                                              Acorda Therapeutics, Inc.???s (ACOR) shares were down almost 21.5% after the U.S. District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug, Ampyra.

                                                Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

                                                Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.

                                                  Arpita Dutt headshot

                                                  Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

                                                  Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.